The development of molecular epidemiology to elucidate cancer risk and prognosis: A historical perspective

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 2, 2010, Pages 84-91

  Ambrosone, Christine B ^a   Harris, Curtis C ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker; Cancer; Cancer prognosis; Chemical carcinogenesis; Molecular epidemiology; Polymorphism

Indexed keywords

4 BIPHENYLAMINE; ACYLTRANSFERASE; AFLATOXIN; ALPHA TOCOPHEROL; BENZO[A]PYRENE; CARCINOGEN; CAROTENOID; COTININE; CYTOCHROME P450 2D6; DEBRISOQUINE; DNA; DNA FRAGMENT; HEMOGLOBIN; ISONIAZID; MANGANESE SUPEROXIDE DISMUTASE; MERCAPTOPURINE; NICOTINE; POLYCYCLIC AROMATIC HYDROCARBON; SELENOPROTEIN P;

BLADDER CANCER; BREAST; BREAST CANCER; BREAST DUCT; BREAST MILK; BRONCHUS; CANCER RISK; CARCINOGENESIS; CELL HETEROGENEITY; CIGARETTE SMOKING; COLON CANCER; DNA POLYMORPHISM; DNA REPAIR; DNA REPLICATION; DRUG METABOLISM; ENDOMETRIUM; ENZYME POLYMORPHISM; EPITHELIUM CELL; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LUNG CANCER; LYMPHOMA; MASS SPECTROMETRY; METABOLISM; MOLECULAR EPIDEMIOLOGY; ONCOGENE; OXIDATION; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATE; RADIOIMMUNOASSAY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

EID: 77954648844     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Nebert DW. Pharmacogenetics and Pharmacogenomics: Why is this Relevant to the Clinical Geneticist? Clin.Genet. 1999; 56(4):247-258.
2. Vogel F. Moderne Probleme Der Humangenetik. Ergeb Inn Med Kinderheilkd 1959; 1252-125.
3. Weber WW and Cohen SN. The Mechanism of Isoniazid Acetylation by Human NAcetyltransferase. BBA - Enzymology 1968; 151 (1):276-278.
4. Idle JR, Mahgoub A, Lancaster R and Smith RL. Hypotensive Response to Debrisoquine and Hydroxylation Phenotype. Life Sci. 1978; 22 (11):979-984.
5. Mulvihill JJ. Host Factors in Human Lung Tumors: An Example of Ecogenetics in Oncology. J.Natl.Cancer Inst. 1976; 57(1):3-7.
6. Motulsky AG. Pharmacogenetics and Ecogenetics. the Problem and its Scope. Hum.Genet. 1978; 45(SUPPL. 1):1-3.
7. Omenn GS. Ecogenetics: A View from the U.S. President's Science Advisory Office. Hum.Genet. 1978; 45(SUPPL. 1):179-184.
8. Harris CC, Mulvihill JJ, Thorgeirsson SS and Minna JD. Individual Differences in Cancer Susceptibility. Ann.Intern.Med. 1980; 92(6):809-825.
9. Mulvihill JJ and Tulinius H. Cancer Ecogenetics: Studying Genetic and Environment Interactions through Epidemiology. Int.J.Epidemiol. 1987; 16 (3):337-340.
10. Harris CC, Autrup H, Connor R, Barrett LA, McDowell EM and Trump BF. Interindividual Variation in Binding of Benzo[a]Pyrene to DNA in Cultured Human Bronchi. Science 1976; 194 (4269):1067-1069.
11. Perera FP and Weinstein IB. Molecular Epidemiology and Carcinogen-DNA Adduct Detection: New Approaches to Studies of Human Cancer Causation. J.Chronic Dis. 1982; 35(7):581-600.
12. Harris CC, Vahakangas K, Autrup H, Trivers GE, Shamsuddin AK, Trump BF, Boman BM and Mann DL. Biochemical and Molecular Epidemiology of Human Cancer Risk. Monogr.Pathol. 1985; (26):140-167.
13. Wild CP. Environmental Exposure Measurement in Cancer Epidemiology. Mutagenesis 2009; 24 (2):117-125.
14. Ross RK, Yuan J-, Yu MC, Wogan GN, Qian G-, Tu J-, Groopman JD, Gao Y- and Henderson BE. Urinary Aflatoxin Biomarkers and Risk of Hepatocellular Carcinoma. Lancet 1992; 339 (8799):943-946.
15. Harris CC, Vahakangas K and Newman MJ. Detection of Benzo[a]Pyrene Diol Epoxide-DNA Adducts in Peripheral Blood Lymphocytes and Antibodies to the Adducts in Serum from Coke Oven Workers. Proc.Natl.Acad.Sci.U.S.A. 1985; 82 (19):6672-6676.
16. Beyerbach A, Rothman N, Bhatnagar VK, Kashyap R and Sabbioni G. Hemoglobin Adducts in Workers Exposed to Benzidine and Azo Dyes. Carcinogenesis 2006; 27(8):1600-1606.
17. Li D, Wang M, Dhingra K and Hittelman WN. Aromatic DNA Adducts in Adjacent Tissues of Breast Cancer Patients: Clues to Breast Cancer Etiology. Cancer Res. 1996; 56(2):287-293.
18. Pfau W, Stone EM, Brockstedt U, Carmichael PL, Marquardt H and Phillips DH. DNA Adducts in Human Breast Tissue: Association with N- Acetyltransferase-2 (NAT2) and NAT1 Genotypes. Cancer Epidemiology Biomarkers and Prevention 1998; 7(11):1019-1025.
19. Thompson PA, Demarini DM, Kadlubar FF, McClure GY, Brooks LR, Green BL, Fares MY, Stone A, David Josephy P and Ambrosone CB. Evidence for the Presence of Mutagenic Arylamines in Human Breast Milk and DNA Adducts in Exfoliated Breast Ductal Epithelial Cells. Environ.Mol.Mutagen. 2002; 39(2-3):134-142.
20. Harris CC, Weston A, Willey JC, Trivers GE and Mann DL. Biochemical and Molecular Epidemiology of Human Cancer: Indicators of Carcinogen Exposure, DNA Damage, and Genetic Predisposition. Environ.Health Perspect. 1987; 75109-119.
21. Hulka BS, Wilcosky TC and Griffith JD: Biological Markers in Epidemiology. Edited by Anonymous New York, New York, Oxford University Press, Inc., 1990.
22. Schulte PA, Hurst RE, Rao JY, Perera FP, Vineis P, Vogt RE, Droz PO, Rothman N, Schottenfeld D, Hertzbert VS, Russek-Cohen E, Winn DM, Gunter EW, Hattis D, Silver K, Santella RM, Harrison LH, Griffin DE, Austin MA, Khoury MJ, Dorr TM, Lemasters GK, Tockman MS, Gupta PK, Pressman NJ, Mulshine JL, Hemstreet GP, Asal NR, Griffith JD, Garry VF, Tamburro CH, Wong JL, Mastin JP, Henningsen GM and Fine LJ: Molecular Epidemiology: Principles and Practices. Edited by Schulte PA and FP Perera. San Diego, Academic Press, Inc, 1993.
23. Lower Jr. GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE and Bryan GT. N-Acetyltransferase Phenotype and Risk in Urinary Bladder Cancer: Approaches in Molecular Epidemiology. Preliminary Results in Sweden and Denmark. Int.J.Epidemiol. 2007; 36(1):11-18.
24. Cartwright RA, Glashan RW and Rogers HJ. Role of N-Acetyltransferase Phenotypes in Bladder Carcinogenesis: A Pharmacogenetic Epidemiological Approach to Bladder Cancer. Lancet 1982; 2(8303):842-846.
25. Kawajiri K, Nakachi K, Imai A, Yoshii A, Shinoda N and Watanabe J. Identification of Genetically High Risk Individuals to Lung Cancer by DNA Polymorphisms of the Cytochrome P450IA1 Gene. FEBS Lett. 1990; 263(1):131-133.
26. Nakachi K, Imai K, Hayashi S- and Kawajiri K. Polymorphisms of the CYP1A1 and Glutathione S-Transferase Genes Associated with Susceptibility to Lung Cancer in Relation to Cigarette Dose in a Japanese Population. Cancer Res. 1993; 53 (13):2994-2999.
27. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P and Talaska G. Genetically Based NAcetyltransferase Metabolic Polymorphism and Low-Level Environmental Exposure to Carcinogens. Nature 1994; 369(6476):154-156.
28. Shields PG and Harris CC. Molecular Epidemiology and the Genetics of Environmental Cancer. JAMA 1991; 266(5):681-687.
29. Ambrosone CB and Kadlubar FF. Toward an Integrated Approach to Molecular Epidemiology. Am.J.Epidemiol. 1997; 146(11):912-918.
30. Ambrosone CB and Kadlubar FF. Formation of a Molecular Epidemiology Group? Cancer Epidemiology Biomarkers and Prevention 1997; 6 (8):651-653.
31. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA and Shields PG. Cigarette Smoking, NAcetyltransferase 2 Genetic Polymorphisms, and Breast Cancer Risk. JAMA 1996; 276(18):1494-1501.
32. Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG and Chang-Claude J. Cigarette Smoking, Acetyltransferase 2 Genotypes, and Breast Cancer Risk: Pooled Analysis and Meta-Analysis. Cancer Epidemiology Biomarkers and Prevention 2008; 17(1):15-26.
33. Ioannidis JPA. Common Genetic Variants for Breast Cancer: 32 Largely Refuted Candidates and Larger Prospects. J.Natl.Cancer Inst. 2006; 98(19):1350-1353.
34. Ambrosone CB. The Promise and Limitations of Genome-Wide Association Studies to Elucidate the Causes of Breast Cancer. Breast Cancer Research: BCR 2007; 9(6):114.
35. Hunter DJ. Gene-Environment Interactions in Human Diseases. Nature Reviews Genetics 2005; 6(4):287-298.
36. Le Marchand L, Hankin JH, Pierce LM, Sinha R, Nerurkar PV, Franke AA, Wilkens LR, Kolonel LN, Donlon T, Seifried A, Custer LJ, Lum-Jones A and Chang W. Well-done Red Meat, Metabolic Phenotypes and Colorectal Cancer in Hawaii. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis 2002; 506-507205-214.
37. Ma X, Chen C, Xiong H, Fan J, Li Y, Lin H, Xu R, Huang G and Xu B. No Association between SOD2 Val16Ala Polymorphism and Breast Cancer Susceptibility: A Meta-Analysis Based on 9,710 Cases and 11,041 Controls. Breast Cancer Res.Treat. 2010; 1-6.
38. Cai Q, Shu XO, Wen W, Cheng JR, Dai Q, Gao YT and Zheng W. Genetic Polymorphism in the Manganese Superoxide Dismutase Gene, Antioxidant Intake, and Breast Cancer Risk: Results from the Shanghai Breast Cancer Study. Breast Cancer Research: BCR 2004; 6(6):R647-655.
39. Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T and Shields PG. Manganese Superoxide Dismutase (MnSOD) Genetic Polymorphisms, Dietary Antioxidants, and Risk of Breast Cancer. Cancer Res. 1999; 59602-606.
40. Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA and Hunter DJ. Manganese Superoxide Dismutase Polymorphism, Plasma Antioxidants, Cigarette Smoking, and Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention 2004; 13(6):989-996.
41. Liwei L, Chunyu L and Ruifa H. Association between Manganese Superoxide Dismutase Gene Polymorphism and Risk of Prostate Cancer: A Meta-Analysis. Urology 2009; 74(4):884-888.
42. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman Jr. JW and Giovannucci E. Manganese Superoxide Dismutase (MnSOD) Gene Polymorphism, Interactions with Carotenoid Levels and Prostate Cancer Risk. Carcinogenesis 2008; 29(12):2335-2340.
43. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ and Ma J. Manganese Superoxide Dismutase Polymorphism, Prediagnostic Antioxidant Status, and Risk of Clinical Significant Prostate Cancer. Cancer Res. 2005; 65(6):2498-2504.
44. Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J and Albanes D. Manganese Superoxide Dismutase (MnSOD) Polymorphism, Alpha-Tocopherol Supplementation and Prostate Cancer Risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (Finland). Cancer Causes Control 2003; 14513-518.
45. Cooper ML, Adami H-, Grönberg H, Wiklund F, Green FR and Rayman MP. Interaction between Single Nucleotide Polymorphisms in Selenoprotein P and Mitochondrial Superoxide Dismutase Determines Prostate Cancer Risk. Cancer Res. 2008; 68(24):10171-10177.
46. Druesne-Pecollo N, Tehard B, Mallet Y, Gerber M, Norat T, Hercberg S and Latino-Martel P. Alcohol and Genetic Polymorphisms: Effect on Risk of Alcohol-Related Cancer. The Lancet Oncology 2009; 10(2):173-180.
47. Relling MV, Hancock ML, Boyett JM, Pui C- and Evans WE. Prognostic Importance of 6- Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. Blood 1999; 93(9):2817-2823.
48. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE and Ratain MJ. Genetic Variants in the UDP-Glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan. J.Clin.Oncol. 2004; 22 (8):1382-1388.
49. Rebbeck TR, Ambrosone CB and Shields PG: Molecular Epidemiology: Applications in Cancer and Other Human Diseases. Edited by Rebbeck TR, Ambrosone CB and Sheilds PG. New York, NY, Informa Healthcare USA, Inc., 2008.
50. Demark-Wahnefried W and Jones LW. Promoting a Healthy Lifestyle among Cancer Survivors. Hematol.Oncol.Clin.North Am. 2008; 22(2):319-342.
51. Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al-Delaimy WK, Bardwell WA, Carlson RW, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L and Stefanick ML. Influence of a Diet very High in Vegetables, Fruit, and Fiber and Low in Fat on Prognosis Following Treatment for Breast Cancer: The Women's Healthy Eating and L i v ing (WHEL) Randomi zed Trial. J.Am.Med.Assoc. 2007; 298(3):289-298.
52. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL and Elashoff RM. Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results from the Women's Intervention Nutrition Study. J.Natl.Cancer Inst. 2006; 98(24):1767-1776.
53. Ulrich CM and Ambrosone CB: Molecular Epidemiological Designs for Prognosis. In: Molecular Epidemiology: Applications in Cancer and Other Human Diseases. Edited by Rebbeck TR, Ambrosone CB and Shields PG. New York, NY, Informa Healthcare USA, Inc., 2008, pp. 41-52.
54. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D. Molecular Portraits of Human Breast Tumours. Nature 2000; 406 (6797):747-752.
55. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P and Borresen-Dale AL. Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications. Proc.Natl.Acad.Sci.U.S.A. 2001; 98(19):10869-10874.